Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Managing acute and long-term side effects in checkpoint inhibitors for melanoma

Karijn Suijkerbuijk • 16 Sep 2024
ESMO 2024
Melanoma Skin Cancer

Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands, comments on the importance of effectively managing acute side effects of melanoma treatments without compromising patient responses. She highlights the complexity of long-term side effects, noting that more data is needed to understand their impact on patients. Unlike traditional immunosuppression, these side effects require tailored support strategies to ensure optimal patient care and quality of life. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Karijn Suijkerbuijk

NADINA: promising neoadjuvant immunotherapy strategies for melanoma
2:58
NADINA: promising neoadjuvant immunotherapy strategies for melanoma
Karijn Suijkerbuijk • 16 Sep 2024
10-year insights from KEYNOTE-006 and CHECKMATE 067 trials in melanoma
2:53
10-year insights from KEYNOTE-006 and CHECKMATE 067 trials in melanoma
Karijn Suijkerbuijk • 16 Sep 2024
Challenges managing treatment related adverse events in acral and mucosal melanomas
2:44
Challenges managing treatment related adverse events in acral and mucosal melanomas
Karijn Suijkerbuijk • 28 Nov 2023
The role of immunotherapies in advanced acral and mucosal melanoma
3:00
The role of immunotherapies in advanced acral and mucosal melanoma
Karijn Suijkerbuijk • 28 Nov 2023

Related Videos

Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
2:41
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
Alexandra Haugh • 30 May 2026
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
1:05
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
James Smithy • 31 May 2026
Optimal timing of ctDNA dynamics to prognosticate ICI efficacy in melanoma
1:26
Optimal timing of ctDNA dynamics to prognosticate ICI efficacy in melanoma
Vincent Ma • 31 May 2026
Phase Ib/II trial of PHP therapy with nivo/rela in metastatic melanoma and liver metastasis
1:42
Phase Ib/II trial of PHP therapy with nivo/rela in metastatic melanoma and liver metastasis
Vincent Ma • 31 May 2026
The content of VJOncology is intended for healthcare professionals